222 related articles for article (PubMed ID: 37585673)
21. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
Storgard R; Markova A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
[TBL] [Abstract][Full Text] [Related]
22. Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.
Zizi N; Elmrahi A; Dikhaye S; Fihmi N; Alami Z
Tunis Med; 2015 Jul; 93(7):413-5. PubMed ID: 26757493
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
24. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
[TBL] [Abstract][Full Text] [Related]
26. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
[TBL] [Abstract][Full Text] [Related]
27. Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review.
Zhang M; Wu R; Jia M; Sun S; Zhang L; Tang T
Medicine (Baltimore); 2023 Oct; 102(41):e35659. PubMed ID: 37832081
[TBL] [Abstract][Full Text] [Related]
28. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab.
Chen PY; Li ZY; Cai SQ
Front Immunol; 2023; 14():1188523. PubMed ID: 37600791
[TBL] [Abstract][Full Text] [Related]
30. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
31. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
32. [Vemurafenib-induced toxic epidermal necrolysis].
Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
[TBL] [Abstract][Full Text] [Related]
33. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.
Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J
Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729
[TBL] [Abstract][Full Text] [Related]
34. Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients.
Ma KS; Saeed HN; Chodosh J; Wang CW; Chung YC; Wei LC; Kuo MT; Liang CM; Chang JW; Chung WH; Chen CB; Ma DH
Ocul Surf; 2021 Oct; 22():47-50. PubMed ID: 34216790
[No Abstract] [Full Text] [Related]
35. Bronchiolitis obliterans following toxic epidermal necrolysis: a case report.
Khanal UP; Roy A; Sharma AK
J Med Case Rep; 2021 Mar; 15(1):159. PubMed ID: 33781322
[TBL] [Abstract][Full Text] [Related]
36. [Drug-induced toxic epidermal necrolysis with secondary aspergillus fumigatus infection: a case report].
Zhang S; Liu XY; Zhang JZ; Cai L; Zhou C
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):977-980. PubMed ID: 31624410
[TBL] [Abstract][Full Text] [Related]
37. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
38. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
[TBL] [Abstract][Full Text] [Related]
39. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
40. Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review.
Zhou S; Zhang Z; Feng X; Zhao C; Jiang L
Front Pharmacol; 2023; 14():1276788. PubMed ID: 38161699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]